Cargando…

The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription Data

INTRODUCTION: This study describes real-world treatment patterns in Germany for brolucizumab, an anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS: This single-arm retrospective cohort study used German patient-level prescrip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liegl, Raffael G., Karcher, Helene, Chetty-Mhlanga, Shala, Igwe, Franklin, Freitas, Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834462/ https://www.ncbi.nlm.nih.gov/pubmed/36327000 http://dx.doi.org/10.1007/s40123-022-00596-7

Ejemplares similares

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab
por: Igwe, Franklin, et al.
Publicado: (2022)

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis
por: Finger, Robert P., et al.
Publicado: (2022)

Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Impact of Adolescents’ Screen Time and Nocturnal Mobile Phone-Related Awakenings on Sleep and General Health Symptoms: A Prospective Cohort Study
por: Foerster, Milena, et al.
Publicado: (2019)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Brolucizumab for macular degeneration
Publicado: (2020)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
por: Zubricky, Ryan, et al.
Publicado: (2023)

Erratum: Side Effects of Brolucizumab
Publicado: (2022)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Is This a 737 Max Moment for Brolucizumab?
por: Rosenfeld, Philip J., et al.
Publicado: (2020)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence
por: Wykoff, Charles C., et al.
Publicado: (2023)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
por: Karasavvidou, Evdoxia-Maria, et al.
Publicado: (2022)

Comment on: Is this a 737 Max Moment for Brolucizumab
por: Kayath, Marcia, et al.
Publicado: (2021)

Bilaterale Vaskulitis nach intravitrealer Gabe von Brolucizumab
por: Kessler, L. J., et al.
Publicado: (2021)

Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK
por: Tran, Trung N., et al.
Publicado: (2020)

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
por: Haug, Sara J., et al.
Publicado: (2020)

Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie
por: Holz, F. G., et al.
Publicado: (2021)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

Retinal pigment epithelial tear following intravitreal injection of brolucizumab
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
por: Mukai, Ryo, et al.
Publicado: (2022)

Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection
por: Ueta, Yoshiki, et al.
Publicado: (2023)

A prospective cohort study of school-going children investigating reproductive and neurobehavioral health effects due to environmental pesticide exposure in the Western Cape, South Africa: study protocol
por: Chetty-Mhlanga, Shala, et al.
Publicado: (2018)

Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders
por: Gauld, Natalie J.
Publicado: (2019)

Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study
por: Iyer, Prashanth G., et al.
Publicado: (2020)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Assessment of the Prescriptions of Systemic Antibiotics in Primary Dental Care in Germany from 2017 to 2021: A Longitudinal Drug Utilization Study
por: Gradl, Gabriele, et al.
Publicado: (2022)

Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence
por: Rosner, Bastian, et al.
Publicado: (2019)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation
por: Patel, Nimesh A., et al.
Publicado: (2020)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_au90sh1lnp3iik8ql7ga28o75m